Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft

Publications in peer reviewed Journal of Immunology and Regenerative Medicine and Clinical Oral Implants Research  Adds to body of evidence for MagnetOs, using data from human and animal models Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today announced the publication of key scientific data on the efficacy of […]

continue reading

Kuros Biosciences Announces Changes to Executive Management Team

Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the appointment of Daniel Geiger as Chief Financial Officer (CFO) ad interim, effective February 17, 2023. Daniel Geiger succeeds Michael Grau, who will handover his CFO position. Joost de Brujin, Chief Executive Officer of Kuros, said: "We are honoured […]

continue reading

Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH

. First investigational trial of drug-biologic bone graft for spinal fusion No drug-related Serious Adverse Events (SAEs) reported in randomized stage of the trial Enrollment of additional 20 patients for second non-randomized stage underway Potential to address a major commercial opportunity Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, […]

continue reading

Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules

Preliminary data shows 78% fusion rate vs 42% for autograft and 55-71% for other synthetic bone grafts  Level 1 clinical study compares MagnetOs Granules to local autograft in patients undergoing posterolateral lumbar fusion  First of five randomized controlled Level 1 trials for MagnetOs to complete enrolment  Kuros Biosciences (“Kuros” or the “Company”), a leader in […]

continue reading

Kuros reports 73% increase in MagnetOs sales in first nine months of 2022

Total product sales grow to CHF 8.9 million in the first nine months of 2022 Reaches major milestone of 10,000 patients treated with MagnetOs Positive first clinical data from planned randomized controlled trials Full commercial launch of MagnetOs Flex Matrix that recently received the Spine Technology Award from Orthopedics This Week With recent PIPE cash […]

continue reading

Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week

. MagnetOs Flex Matrix recognized as exemplary and innovative spine surgery product   Rounds out MagnetOs portfolio to provide more solutions for surgeons  Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today announces that it has received the 2022 Spine Technology Award from the widely-read industry publication Orthopedics This […]

continue reading

Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting

  First clinical data from five planned randomized controlled trials Show favorable fusion rate compared to autograft Launch of MagnetOs Flex Matrix expands perioperative options for surgeons Schlieren (Zurich), Switzerland, 11 October, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it will present compelling clinical […]

continue reading

Kuros Biosciences Appoints Chris Fair as Chief Operating Officer

Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has appointed Chris Fair as Chief Operating Officer (COO). Mr. Fair is a leader in the musculoskeletal and regenerative medicine industry with more than 25 years of experience in overseeing and guiding organizations through development, growth and […]

continue reading

Kuros Biosciences announces successful CHF 6.0 million private placement

Kuros Biosciences AG (SIX:KURN) a leader in next generation bone graft technologies, announced today the successful completion of a CHF 6.0 million capital increase through a private placement of 3,750,000 new shares of Kuros with a par value of CHF 0.10 each (the "New Shares" and the "Placement", respectively). The New Shares have been placed […]

continue reading